Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST) Meeting Abstract

  

Authors:	Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; Rosenbaum, E.; Bartlett, E. K.; Crago, A.; Strong, V.; Singer, S.; Antonescu, C.; Berger, M.; Qin, L. X.; Tap, W. D.; Chi, P.
Abstract Title:	Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
Meeting Title:	ESMO Congress 2024
Journal Title:	Annals of Oncology
Volume:	35
Issue:	Suppl. 2
Meeting Dates:	2024 Sep 13-17
Meeting Location:	Barcelona, Spain
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2024-09-01
Start Page:	S1049
End Page:	S1050
Language:	English
ACCESSION:	WOS:001326612902382
DOI:	10.1016/j.annonc.2024.08.1853
PROVIDER:	wos
Notes:	Meeting Abstract: 1762P -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/224365